Vera Therapeutics will present five company-sponsored abstracts at the American Society of Nephrology Kidney Week 2026 in Denver from October 22 to 25. The final efficacy analysis from the ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in IgA nephropathy will feature in the opening plenary session and a late-breaking poster, while interim adult IgA nephropathy and primary membranous nephropathy results from the Phase 2 PIONEER basket trial will be presented in a late-breaking oral session. TRUTAKNA is approved under accelerated approval to reduce proteinuria in adults with primary IgA nephropathy at risk of disease progression; its long-term effect on kidney-function decline has not been established. The product inhibits BAFF and APRIL, cytokines involved in B-cell activation, and is administered once weekly through a 1-milliliter, 150-milligram autoinjector. Vera also provided safety information, including higher rates of infections and local administration reactions than placebo in clinical trials, and said pediatric safety and effectiveness have not been established.